topsalysin
Recombinant proteinexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00686088)
Timeline
Indications
Mechanism of action
- reactive aldehydeINHIBITOR
reactive aldehyde inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2364656 ↗
Also known as
- prx302
- prx302
- topsalysin
- topsalysin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03081481 | Phase 2 | Jun 1, 2017 | Sophiris Bio Corp, University of London |
| NCT02499848 | Phase 2 | Jul 1, 2015 | Sophiris Bio Corp, University of London |
| NCT01966614 | Phase 3 | Oct 1, 2013 | Sophiris Bio Corp |
| NCT01454349 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2011 | Sophiris Bio Corp |
| NCT00889707 | Phase 2 | Jan 1, 2009 | CanMed Clinical Research Inc., McGill University, Sophiris Bio Corp |
| NCT00686088 | Phase 2 | Feb 1, 2008 | Sophiris Bio Corp |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sophiris Bio Corp | For profit | 6 | 6 | 2 | 2008 |
| University of London | Academic/Hospital | 2 | 0 | 1 | 2015 |
| CanMed Clinical Research Inc. | Academic/Hospital | 1 | 0 | 1 | 2009 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1